title: National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer.
authors.affiliation: Sumanta Kumar Pal, City of Hope Comprehensive Cancer Center, Duarte, CA; Neeraj Agarwal, Huntsman Cancer Institute, Salt Lake City, UT; Stephen Anthony Boorjian, Mayo Clinic, Rochester, MN; Noah M. Hahn, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Arlene O. Siefker-Radtke, Vanderbilt University, Nashville, TN; Peter E. Clark, MD Anderson Cancer Center, Houston, TX; and Elizabeth R. Plimack, Fox Chase Cancer Center, Philadelphia, PA. spal@coh.org.
authors.forename: Sumanta Kumar
authors.initials: SK
authors.lastname: Pal
authors.affiliation: Sumanta Kumar Pal, City of Hope Comprehensive Cancer Center, Duarte, CA; Neeraj Agarwal, Huntsman Cancer Institute, Salt Lake City, UT; Stephen Anthony Boorjian, Mayo Clinic, Rochester, MN; Noah M. Hahn, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Arlene O. Siefker-Radtke, Vanderbilt University, Nashville, TN; Peter E. Clark, MD Anderson Cancer Center, Houston, TX; and Elizabeth R. Plimack, Fox Chase Cancer Center, Philadelphia, PA.
authors.forename: Neeraj
authors.initials: N
authors.lastname: Agarwal
authors.affiliation: Sumanta Kumar Pal, City of Hope Comprehensive Cancer Center, Duarte, CA; Neeraj Agarwal, Huntsman Cancer Institute, Salt Lake City, UT; Stephen Anthony Boorjian, Mayo Clinic, Rochester, MN; Noah M. Hahn, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Arlene O. Siefker-Radtke, Vanderbilt University, Nashville, TN; Peter E. Clark, MD Anderson Cancer Center, Houston, TX; and Elizabeth R. Plimack, Fox Chase Cancer Center, Philadelphia, PA.
authors.forename: Stephen Anthony
authors.initials: SA
authors.lastname: Boorjian
authors.affiliation: Sumanta Kumar Pal, City of Hope Comprehensive Cancer Center, Duarte, CA; Neeraj Agarwal, Huntsman Cancer Institute, Salt Lake City, UT; Stephen Anthony Boorjian, Mayo Clinic, Rochester, MN; Noah M. Hahn, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Arlene O. Siefker-Radtke, Vanderbilt University, Nashville, TN; Peter E. Clark, MD Anderson Cancer Center, Houston, TX; and Elizabeth R. Plimack, Fox Chase Cancer Center, Philadelphia, PA.
authors.forename: Noah M
authors.initials: NM
authors.lastname: Hahn
authors.affiliation: Sumanta Kumar Pal, City of Hope Comprehensive Cancer Center, Duarte, CA; Neeraj Agarwal, Huntsman Cancer Institute, Salt Lake City, UT; Stephen Anthony Boorjian, Mayo Clinic, Rochester, MN; Noah M. Hahn, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Arlene O. Siefker-Radtke, Vanderbilt University, Nashville, TN; Peter E. Clark, MD Anderson Cancer Center, Houston, TX; and Elizabeth R. Plimack, Fox Chase Cancer Center, Philadelphia, PA.
authors.forename: Arlene O
authors.initials: AO
authors.lastname: Siefker-Radtke
authors.affiliation: Sumanta Kumar Pal, City of Hope Comprehensive Cancer Center, Duarte, CA; Neeraj Agarwal, Huntsman Cancer Institute, Salt Lake City, UT; Stephen Anthony Boorjian, Mayo Clinic, Rochester, MN; Noah M. Hahn, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Arlene O. Siefker-Radtke, Vanderbilt University, Nashville, TN; Peter E. Clark, MD Anderson Cancer Center, Houston, TX; and Elizabeth R. Plimack, Fox Chase Cancer Center, Philadelphia, PA.
authors.forename: Peter E
authors.initials: PE
authors.lastname: Clark
authors.affiliation: Sumanta Kumar Pal, City of Hope Comprehensive Cancer Center, Duarte, CA; Neeraj Agarwal, Huntsman Cancer Institute, Salt Lake City, UT; Stephen Anthony Boorjian, Mayo Clinic, Rochester, MN; Noah M. Hahn, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Arlene O. Siefker-Radtke, Vanderbilt University, Nashville, TN; Peter E. Clark, MD Anderson Cancer Center, Houston, TX; and Elizabeth R. Plimack, Fox Chase Cancer Center, Philadelphia, PA.
authors.forename: Elizabeth R
authors.initials: ER
authors.lastname: Plimack
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics*; D020869:Gene Expression Profiling / Q000379:methods*; D020022:Genetic Predisposition to Disease; D006801:Humans; D058990:Molecular Targeted Therapy; D010641:Phenotype; D057285:Precision Medicine; D011237:Predictive Value of Tests; D059467:Transcriptome; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor